Answers are grounded in this paper and cite their sources.
OBJECTIVES: While clinical and endoscopic remission (ER) are established therapeutic targets in ulcerative colitis (UC), endoscopic healing may not fully reflect residual microscopic inflammation. Histologic remission (HR) has been proposed as a deeper marker of disease control and a potential predictor of long-term outcomes. We evaluated whether HR predicts relapses in pediatric UC patients who achieved ER. METHODS: This multicenter retrospective cohort study included pediatric patients with UC (<18 years) who achieved ER (Mayo endoscopic subscore (MES) 0 or 1). HR was defined as a Nancy index score of 0. Patients were stratified into HR and non-HR groups. The primary outcome was clinical relapse, defined as a partial Mayo score ≥3, corticosteroid initiation, requiring treatment escalation, UC-related hospitalization, colectomy or death. Relapse-free survival was analyzed using Kaplan-Meier estimates and Cox proportional hazards models. RESULTS: Among 111 pediatric UC patients with ER, 35 (31.5%) achieved HR. Patients with HR showed significantly improved relapse-free survival than non-HR (log-rank p = 0.015). Multivariable Cox regression demonstrated that both ER (MES 0 vs. 1; hazard ratio 0.57, 95% confidence interval (CI) 0.28-0.94, p = 0.032) and HR (hazard ratio 0.39, 95% CI 0.17-0.91, p = 0.030) independently predicted reduced relapse risk. Notably, even among patients with ER, those with a Nancy index of 0 had superior relapse-free survival versus a score of 1 (p = 0.008). CONCLUSIONS: HR was achieved in only one-third of pediatric patients with UC with ER but was strongly associated with reduced relapse, supporting HR as a treatment target beyond ER.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: